Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

Positive AP26113 progress:

Tapered dose steroids were used to resolve symptoms over 1 week, and patients restarted the drug at 90 mg/d without further pulmonary symptoms, he said. Future studies will employ a step-up approach, initiating the drug at 90 mg/d for 7 days before moving up to 180 mg/d.

http://www.ascopost.com/issues/december-1,-2013/early-evidence-supports-novel-alk-inhibitor-in-patients-with-non%E2%80%93small-cell-lung-cancer-with-brain-metastases.aspx